UMIN-CTR History

Name:  UMIN ID:


Unique ID issued by UMIN UMIN000034869
Receipt number R000039604
Scientific Title A Phase 3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of two dose levels of BCX7353 as an oral treatment for the prevention of attacks in subjects with hereditary angioedema
Date of disclosure of the study information 2018/11/13
Last modified on 2021/10/28 14:42:36

No. Disposal Last modified on Item of update
1 Insert 2018/11/12 19:58:12
2 Update 2018/11/13 17:34:08 Classification by specialty
3 Update 2018/11/14 07:35:19 Division
Nationality of Funding Organization
Nationality of Funding Organization
Research ethics review
Institutions
4 Update 2018/12/06 21:16:50 Institutions
5 Update 2019/03/26 17:50:11 Recruitment status
Date of IRB
6 Update 2019/05/14 18:27:12 1st name of lead principal investigator
1st name of lead principal investigator
Zip code

Last name of contact person

Last name of contact person
Zip code
Division name
Division name
Organization
Organization
Address
Address
Tel
Email
7 Update 2019/10/30 07:40:34 UMIN ID1
8 Update 2020/11/03 13:33:55 UMIN ID2
9 Update 2020/11/05 00:50:41 Narrative objectives1
Narrative objectives1
10 Update 2020/11/05 15:14:31
Last name of contact person

Last name of contact person
Organization
Organization
Zip code
Address
Address
TEL
Email
Name of person sending information
Name of person sending information
Organization
Organization
Division name
Division name
Address
Address
TEL
Email
Organization1
Address1
Tel1
Email1
11 Update 2020/11/05 16:47:35 Address
12 Update 2020/11/05 16:49:27 Address
13 Update 2020/11/27 16:30:26 Recruitment status
Last follow-up date
14 Update 2021/06/23 11:47:04
Last name of contact person

Last name of contact person
TEL
Email
Name of person sending information
Name of person sending information
TEL
Email
15 Update 2021/10/28 14:42:01 Recruitment status
16 Update 2021/10/28 14:42:36 Publication of results
URL related to results and publications
Number of participants that the trial has enrolled